NEW YORK (GenomeWeb) – Becton Dickinson today reported that its second quarter revenues increased around 4 percent year over year driven by growth in its BD Medical and BD Biosciences business segments.

BD reported total revenues of $2.07 billion for the three months ended March 31, up from $2.00 billion for the second quarter of 2013. It fell short of the average analyst estimate of $2.09 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.